Groups Issue Booklet to Help Biotechnology and Pharmaceutical Companies Identify Pipeline Medicines with Doping Potential
IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of Campaign
<0> IFPMAPeter ShelbyAssociate Director, Communications+4122 338 3223orBIOJeff JosephVice President, Communications+1202-962-9200orWADATerence O’RorkeSenior Manager, Media Relations and Communications+1514 904 8820 </0>
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global Biotechnology Industry Organization (BIO) and the World Anti-Doping Agency (WADA) today announced the launch of the campaign, that aims to achieve the goals of the Joint Declaration on Cooperation in the Fight against Doping in Sport (Joint Declaration).
The campaign creates a strong framework of collaboration and encourages the voluntary cooperation of IFPMA and BIO member companies with WADA to readily identify compounds with the potential for misuse by athletes and to stop doping in sport.
The launch of the campaign coincides with the release of the () booklet. This resource provides biotechnology and pharmaceutical companies with practical guidelines to identify compounds with sports-related doping potential before they come to market. The booklet also helps minimize misuse of compounds during clinical trials, facilitates sharing of information and collaboration on communications about medicines with known doping potential. In addition to the booklet, campaign materials include a brochure and frequently asked questions, which provide more insight into industry collaboration against doping in sport.
“The campaign aims to accomplish the goals that were laid out in the Joint Declaration that IFPMA and BIO signed with WADA,” said Eduardo Pisani, IFPMA Director General. “Doping is a public health issue and undermines the integrity of scientific innovation and competitive sports. We are pleased to provide support that will help companies determine if they have products in their pipelines that could be abused by athletes, even before they come to market.”
In July 2010, IFPMA and WADA signed the Joint Declaration to encourage the voluntary cooperation of IFPMA member companies to fight doping in sport and to assist in the development of detection methods. BIO signed on to the Joint Declaration in June 2011. As an extension of this Declaration, the booklet and the campaign serve as a manual to help companies identify compounds in all stages of development with the potential for misuse and allow for the sharing of information between the companies and WADA in order to develop testing and detection methods to detect illegal or illicit use by athletes.
“Working closely with biotechnology and pharmaceutical companies to identify new potential doping compounds before they are commercially available will facilitate much faster development of detection methods,” said David Howman, Director General of WADA. “In addition, the booklet will allow the pharmaceutical industry to ensure their work is directed at developing and delivering treatments and medicines for therapeutic purposes.”
For a copy of the booklet and campaign materials, please visit .
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 1.3 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
IFPMA manages global initiatives including: IFPMA Developing World Health Partnerships studies and identifies trends for the research-based pharmaceutical industry’s long-term partnership programs to improve health in developing countries, IFPMA Code of Practice sets unsurpassed standards for interactions with the healthcare community, IFPMA Clinical Trials Portal helps patients and health professionals find out about on-going clinical trials and trial results.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
The World Anti-Doping Agency (WADA) is the international independent organization created in 1999 to promote, coordinate, and monitor the fight against doping in sport in all its forms.